First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-10-15
DOI
https://doi.org/10.3389/fimmu.2025.1667793
Citations
3
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
3.97
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials

Jinhai Shen, Yonghe Liao, Bo Luo, Yuxuan Lin
3 citations
Frontiers in Immunology
Hepatocellular Carcinoma Treatment and Prognosis
3.97
article

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials

Jinhai Shen, Yonghe Liao, Bo Luo, Yuxuan Lin
article en
3 citations

Abstract

No abstract available for this paper.
Frontiers in ImmunologyVol. 16
Guangxi Medical University (CN), China Pharmaceutical University (CN), First Affiliated Hospital of GuangXi Medical University (CN)
Openalex Percentile: Top 5%
Hepatocellular Carcinoma Treatment and Prognosis
3.97
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.